A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naive Subjects With Chronic HCV Infection

Trial Profile

A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naive Subjects With Chronic HCV Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Sofosbuvir (Primary) ; Velpatasvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 10 Nov 2015 Results published in the Annals of Internal Medicine
    • 21 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Apr 2014 Results will be presented at the 49th Annual Meeting of the European Association for the Study of the Liver (The International Liver Congress 2014) according to a Gilead Sciences media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top